I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

计划入组 1,500 人 · 首次发布于 2020 年 7 月 27 日

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

计划入组 5,000 人 · 首次发布于 2010 年 1 月 5 日

Spy II Clinical Registry

计划入组 297 人 · 首次发布于 2008 年 9 月 12 日

SPY-003

SPY-001

BEAT COVID LLC

United States

Tradr 2X Long SPY Monthly ETF

Universitetet i Oslo

Norway

I-SPY COVID Trial: Adaptive Platform Design Accelerates COVID-19 Therapeutic Discovery

I-SPY 2.2 Trial Design Shows Promise in Identifying Less Toxic Breast Cancer Therapies

I-SPY 2.2 Trial Revolutionizes Breast Cancer Treatment with Patient-Centered Design